Toll Free: 1-888-928-9744
Published: Dec, 2014 | Pages:
54 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)
Anal Cancer - Pipeline Review, H2 2014 Summary Global Markets Direct's, 'Anal Cancer - Pipeline Review, H2 2014', provides an overview of the Anal Cancer's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Anal Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Anal Cancer and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Anal Cancer - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Anal Cancer and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Anal Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Anal Cancer pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Anal Cancer - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Anal Cancer pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Anal Cancer Overview 6 Therapeutics Development 7 Pipeline Products for Anal Cancer - Overview 7 Pipeline Products for Anal Cancer - Comparative Analysis 8 Anal Cancer - Therapeutics under Development by Companies 9 Anal Cancer - Pipeline Products Glance 10 Clinical Stage Products 10 Early Stage Products 11 Anal Cancer - Products under Development by Companies 12 Anal Cancer - Companies Involved in Therapeutics Development 13 Advaxis, Inc. 13 Amgen Inc. 14 Eli Lilly and Company 15 ISA Pharmaceuticals B.V. 16 MedImmune, LLC 17 THERAVECTYS SA 18 Anal Cancer - Therapeutics Assessment 19 Assessment by Monotherapy Products 19 Assessment by Combination Products 20 Assessment by Target 21 Assessment by Mechanism of Action 23 Assessment by Route of Administration 25 Assessment by Molecule Type 27 Drug Profiles 29 ADXS-HPV - Drug Profile 29 Product Description 29 Mechanism of Action 29 R&D Progress 29 durvalumab + tremelimumab - Drug Profile 32 Product Description 32 Mechanism of Action 32 R&D Progress 32 ISA-101 - Drug Profile 34 Product Description 34 Mechanism of Action 34 R&D Progress 34 LY-2606368 - Drug Profile 35 Product Description 35 Mechanism of Action 35 R&D Progress 35 panitumumab - Drug Profile 36 Product Description 36 Mechanism of Action 36 R&D Progress 36 Vaccine for HPV Associated Cancers - Drug Profile 39 Product Description 39 Mechanism of Action 39 R&D Progress 39 Anal Cancer - Recent Pipeline Updates 40 Anal Cancer - Dormant Projects 52 Appendix 53 Methodology 53 Coverage 53 Secondary Research 53 Primary Research 53 Expert Panel Validation 53 Contact Us 54 Disclaimer 54
List of Tables Number of Products under Development for Anal Cancer, H2 2014 7 Number of Products under Development for Anal Cancer - Comparative Analysis, H2 2014 8 Number of Products under Development by Companies, H2 2014 9 Comparative Analysis by Clinical Stage Development, H2 2014 10 Comparative Analysis by Early Stage Development, H2 2014 11 Products under Development by Companies, H2 2014 12 Anal Cancer - Pipeline by Advaxis, Inc., H2 2014 13 Anal Cancer - Pipeline by Amgen Inc., H2 2014 14 Anal Cancer - Pipeline by Eli Lilly and Company, H2 2014 15 Anal Cancer - Pipeline by ISA Pharmaceuticals B.V., H2 2014 16 Anal Cancer - Pipeline by MedImmune, LLC, H2 2014 17 Anal Cancer - Pipeline by THERAVECTYS SA, H2 2014 18 Assessment by Monotherapy Products, H2 2014 19 Assessment by Combination Products, H2 2014 20 Number of Products by Stage and Target, H2 2014 22 Number of Products by Stage and Mechanism of Action, H2 2014 24 Number of Products by Stage and Route of Administration, H2 2014 26 Number of Products by Stage and Molecule Type, H2 2014 28 Anal Cancer Therapeutics - Recent Pipeline Updates, H2 2014 40 Anal Cancer - Dormant Projects, H2 2014 52
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.